California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
SAN FRANCISCO, Oct. 25, 2016 -- Hagens Berman Sobol Shapiro LLP reminds investors in Alnylam Pharmaceuticals, Inc. that the firm is investigating possible securities law violations by the Company and its officers.
If you purchased or otherwise acquired securities of ALNY before October 6, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/ALNY
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On October 5, 2016 Alnylam filed its Form 8-K with the SEC publicly announcing it would discontinue testing of one of its key drugs, Revusiran, “upon the recommendation of the ENDEAVOUR Phase 3 study Data Monitoring Committee (DMC).” TheStreet reported on October 6, 2016 that “[w]hen independent monitors peeked into the study results, they found 18 patients had died, more treated with revusiran than with a placebo, although how many more Alnylam won’t disclose.”
This news drove the price of Alnylam shares down over 45% during intra-day trading on October 6, 2016.
“We’re looking into when the deaths occurred relative to management’s statements about the drug’s development,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Alnylam should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
